AI assistant
Pasithea Therapeutics Corp. — Director's Dealing 2024
Apr 6, 2024
35389_dirs_2024-04-05_5e69906a-118e-4a1b-b951-6e5d6f7b8d50.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4/A — Form 4/A
Issuer: Pasithea Therapeutics Corp. (KTTA)
CIK: 0001841330
Period of Report: 2024-03-01
Reporting Person: Novak Alfred J (Director)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2024-03-01 | Stock Option (right to buy) | $8.13 | A | 5000 | Acquired | 2034-02-28 | Common Stock (5000) | Direct |
Footnotes
F1: The sole purpose of this Form 4/A is to correct the exercise price, which was previously reported erroneously as $8.34 per share. The correct exercise price, based upon the closing price of the Issuer's common stock, par value $0.0001 per share ("Common Stock"), on March 1, 2024, was $8.13 per share.
F2: The option award (the "Option") was made in accordance with the terms of the Issuer's 2023 Stock Incentive Plan. The shares of Common Stock underlying the Option will vest at the rate of 33% upon the one-year anniversary of the date of grant and 33% on each successive one-year anniversary thereafter; provided, that the Reporting Person remains a director of the Issuer through such vesting date.